Discontinuation of tamsulosin treatment in men with lower urinary tract symptoms: A pilot study

Urologia Internationalis

Volumn 76, Issue 4, 2006, Pages 304-308

  Kobayashi, Minoru ^a,b   Tokue, Akihiko ^b   Morita, Tatsuo ^b  

^a Sano Kosei General Hospital   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

International Prostate Symptom Score; Lower urinary tract symptoms; Quality of life index; Tamsulosin, discontinuation

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SCORING SYSTEM; SYMPTOM; TRANSRECTAL ULTRASONOGRAPHY; URETHRA; URINARY TRACT DISEASE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; PILOT PROJECTS; PROSTATIC HYPERPLASIA; SULFONAMIDES; URINATION DISORDERS;

EID: 33646507485     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092052     Document Type: Article

References (16)

1. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 1996;16:21-28.
2. 1-adrenergic receptor subtypes. Prostate 1997;33:55-59.
3. Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997;80:597-605.
4. Harada K, Ohmori M, Fujimura A: Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans. Naunyn Schmiedebergs Arch Pharmacol 1996;354:557-561.
5. De Mey C, Michel MC, McEwen JA, Moreland T: A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481-488.
6. Lepor H: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51:901-906.
7. Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, European Tamsulosin Study Group: Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001;166:1358-1363.
8. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
9. Fabricius PG, Mannaford JM: Placebo-controlled study of terazosin in the treatment of benign prostate hyperplasia with 2-year follow-up. Br J Urol 1992;70:10-16.
10. Kaplan SA, Reis RB, Cologna A, Saudi HJ, Martins ACP, Kohn IJ, Te AE: Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. Urology 1998;52:12-16.
11. Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D: Intermittent tamsulosin treatment in men with treatment lower urinary tract symptoms. J Urol 2005;173:155-157.
12. Baldwin KC, Ginsberg PC, Harkaway RC: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol Int 2001;66:84-88.
13. Baldwin KC, Ginsberg PC, Roehrborn CG: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58:203-209.
14. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44:461-466.
15. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA: Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002;167:1734-1739.
16. Hong SJ, Ko WJ, Kim SI, Chung BH: Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol 2003;44:94-99.